Highest-materiality recent filing
Wave Life Sciences completes redomiciliation to Delaware; shares trade under WVE on Nasdaq
On Aug 7, 2026, Wave Life Sciences, Inc. (Delaware) became parent of Wave Life Sciences Ltd. (Singapore) via scheme of arrangement; shares exchanged 1:1.
Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006
Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.
WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.
Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026
Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).
Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial
Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.
Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026
Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.
Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026
Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.
Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones
Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.
Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028
Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.
Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.
Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction
WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.
WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.
WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).
Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study
200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels
Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track
Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.
Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD
Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.
Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026
TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.
Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025
Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.
Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved
Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).
Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006
Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.
Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program
Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.
Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants
Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.
Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.
Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.
Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated
SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).
Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track
Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.
Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.
Wave Life Sciences closes public offering of 23M shares, raising $115M gross
Underwriters fully exercised option to purchase 3M additional shares, increasing total to 23M.
Underwritten public offering of 20M ordinary shares at $5.00/share, gross proceeds ~$100M; 30-day option for additional 3M shares.
Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006
Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.
Wave Life Sciences unveils INHBE siRNA for obesity, targets 5 new clinical candidates by 2025
New GalNAc-siRNA program targeting INHBE for metabolic disorders including obesity; expects clinical candidate in 4Q 2024.
Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration
Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.
On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.
Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.
Max materiality 0.90 · Median 0.70 · Most common event other_material